Authors :
Priyadarshini Chaudhari; Mayur Prajapati; Nidhi Patel; Dhruv Patel; Anjali Prajapati; Khushbu Patel
Volume/Issue :
Volume 9 - 2024, Issue 12 - December
Google Scholar :
https://tinyurl.com/ys437cw6
Scribd :
https://tinyurl.com/b7kmz2kf
DOI :
https://doi.org/10.5281/zenodo.14539862
Abstract :
Diabetes refers to a metabolic disorder
identified by Hyperglycemia. Dipeptidyl peptidase-4
inhibitors (DPP-4 inhibitors) are also called as Gliptins
are a relatively new class of antidiabetic drugs to treat
type-2 diabetes. Analytical method development and
validation play an indispensable role in analysis and
manufacture of pharmaceuticals. The intent of this
article is to study the reported analytical methods in the
literature for assessment of Dipeptidyl peptidase- 4
inhibitors. This review covers divergent analytical
methods for the estimation of these drugs. Many
spectroscopic and chromatographic techniques are
available for the determination and evaluation of these
drugs in bulk and pharmaceutical preparation. Newly
evolved and advanced chromatographic techniques are
also available for the estimation of these drugs in
biological fluids such as Liquid Chromatography-
Tandem Mass Spectroscopy (LC- MS/MS), Gas
Chromatography- Mass Spectroscopy (GC- MS), High
Performance Liquid Chromatography- Mass
Spectroscopy (HPLC-MS) and Ultra- Fast Liquid
Chromatography (UFLC). The development and
validation of analytical methods is imperative for drug
development studies and even for the development of
drug formulation including stability and degradation
studies and also for the determination of
pharmacokinetic data of these drugs. This review work
summaries the current position of analytical methods for
estimation of these antidiabetic drugs in bulk, dosage
form and biological fluids.
References :
- Ambady Ramachandran and ChamukuttanSnehalatha: “Current scenario of diabetes in India,” J. Diabetes, 2009, 1(1), 18-28.
- Nguyen Si Phuong Thao, “Diabetes overview: symptoms & causes,” Available at https://www.careplusvn.com/en/diabetes-overview-symptoms-causes.
- Kinjal Thakkar, Khushbu Patel, U. B. Patel and Dr. C. N. Patel: “Evogliptin tartrate a new drug of DPP-4 inhibitor: an overview,” WJPR, 2021, 10(5), 1921-1929.
- Amit Sapra and Priyanka Bhandari: “Diabetes mellitus, treasure island (fl), statepearls publishing,” 2023, available at https://www.ncbi.nlm.nih.gov/books/NBK551501/
- Varma D. S. and Dighe P. R.: “analytical methods of anti-diabetic drugs- sitagliptin, saxagliptin, linagliptin, alogliptin, gemifibrozil, troglitazone, pioglitazone, rosiglitazone: a review,”RJPDFT, 2022, 14(4), 324-330.
- Veena D. Singh, S. J. daharwal and Preeti K. Suresh: “A review of instrumental analytical methods to assay active ingredients in multicomponent pharmaceutical formulations,” CJPS, 2014, (1), 27-39.
- Arul Caroline Grace, “Thangavel Prabha and Murugesan J.: Analytical method for determination of Sitagliptin,” an updated review,Int j. pharm. Sci. rev.res, 2017, 43(1),217-225.
- Balamurugan k., kirtimayamishra and suresh r. “Sitagliptin:a literature review on analytical and bioanalytical methods,” Pharma Innov. J,2018, 7(8), 357-361.
- Mohamed Karam Qassas, “Mohammad AmeralMardlnl and Heba Ghazal: A validated HPLC stability indicating method for the determination of Sitagliptin in bulk drug substance and tablets,” Int. Pharm. Sci. Rev. Res., 2015, 32(1), 194-198.
- Dnyaneshwar P. Sonune and Mahesh Kumar Mone, “Isolation, Characterization of degredation products of Sitagliptin an development of validated stability-indicating HPLC assay method for Sitagliptin API and tablets,” IJPSR, 2013, 4(9), 3494-3503.
- Muhammad ASHRAF, Muhammad N. SHAHZAD and Muhammad M. HAYAT “development and validation of an HPLC method for the quantification of Sitagliptin in plasma and tablet dosage form,” Lat. Am. J. Pharm., 2015, 34(3), 1-6.
- Sagar Pamu, SazalPatyar and Lakshmi Thakkalapally: “Development and validation of a novel RP-HPLC analytical method for Sitagliptin determination in human plasma,” J. Pharm. Res. Int., 2021, 33(42B), 92-101.
- Qaiser Iqbal, Sajid Bashir and SyedUmerJan: “Development of rapid resolution HPLC method for the quantitative determination of Sitagliptin in human plasma,” Pak. J. Pharm. Sci., 2018, 31(3), 795-799.
- Sammi Akter, Md. TalebHossain and ArghyaProsunSarkar: “Development and validation of HPLC method for estimation of Sitagliptin the tablet dosage form,” WJPPS, 2015, 11(3), 1880-1889.
- Vandana Gawande Shankar Narvekar and Piyush Rathor: “Simple, rapid RP-HPLC method for estimation of Sitagliptin from urine and its application in pharmacokinetics,” IJB, 2013, 2(10) 1322-1326.
- NusratbanuK. Sheikh, DarshilB. Shah and Dilip G. Maheshwari: “Reviw on analytical method for determination of sitagliptin phosphate in bulk and in different dosage forms,” AJPTI, 2016,04(20), 40-53.
- PradnyaLokhande: “Development and validation of an RP-HPLC method for analysis of sitagliptin,” IJTSRD, 2019, 3(6), 728-732.
- Raja Abhilash Punagoti and Rita Mourya: “Development and validation of new RP-HPLC method for the quantitative estimation of sitagliptin phosphate in bulk and tablet dosage form,” J. Adv. Sci. Res., 2021, 12(3), 301-305.
- Gaddala Deepthi, Dr. Sanjeev KumarSubudhi and D. Snigdha: “RP-HPLC method for development and validation for the determination of sitagliptin in bulk and pharmaceutical dosage form,” IJARMPS, 2019, 4(10), 19-27.
- Wael Abu Dayylh and Mohammed Hamad: “Determination of sitagliptin levels in rats serum by HPLC and its pharmacokinetic investigation in existence of sucralose,” Indonesian J. Pharm., 2010, 29(3), 117-126.
- V. Deepthi, Poornima Y. and Dr. G. Devala Rao: “Stability indicating RP-HPLC method for analysis of sitagliptin in the bulk drug and it’s pharmaceutical dosage form,” Int. J. Pharm. Pharm. Sci.,2013, 5(1), 320-325.
- Sharifa Sultana, Md. Shahadat Hossain and Md.Samiul Islam: “Quantitation of sitagliptin in drug product by validated reversed phase liquid chromatographic technique,” Dhaka Uni. J. Pharma. Sci., 2018, 17(1), 123-129.
- Hari Naga Prasada Reddy Chittireddy, J. V. Shammukha Kumar and Anuradha Bhimireddy: “Development and validation for quantification of 7-Nitroso impurity in sitagliptin by Ultraperformance liquid chromatography with triple quadrupole Mass Spectroscopy,”Molecules, 2022, 27, 8581.
- Gabriel Onn Kit Loh, Emily Yii Ling Wong and Yvonne Tze Fung Tan: “Simple and rapid LC-MS/MS method for determination of sitagliptin in human plasma and application to bioequivalence study,” J. Chromatography B, 2020, 1159,
- Qian Zhao, Bo-ya Wang and Ji Jiang: “Quantification of sitagliptin in human plasma and urine by LC-MS/MS method and its application,”NIH, 2015, 50(6), 714-718.
- Dall Cortivo Lange Alini, Tams GasperinFraciele and Dos Santos Carolina: “Stability-indicating LC assay with determination of system suitability limits by a robustness test for sitagliptin tablets and assessment of cytotoxicity for degradation products,” Curr. Pharma. Anal., 2012, 8(4) 360-367(8).
- K. R. Patil, T A Deshmukh and V R Patil: “A stability indicating HPTLC method development and validation for analysis of sitagliptin as bulk drug and in formulation,” Am. J. Pharm. Tech. Res., 2018, 9(06), 123-135.
- Priyanka D. Patel and Dr. Saurabh S. Pandya: “A review on analytical methods for determination of oral anti-diabetic drugs like biguanides, gliptins and gliflozins in bulk and in pharmaceutical dosage forms,” World J. Pharm. Sci., 2018, 6(1), 29-39.
- P. Ravisankar, G. Mounika and Ch. Devadasu: “A simple validated UV spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form,” J. Chem. Pharm. Sci., 2014, 7(3), 254-258.
- Sachin Patil, B.Ramesh and AR Hareesh: “Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in tablet dosage form,” Asian j. res. Chem., 2010, 3(3), 653-655.
- R Lavanya and Md.yunoos: “Development and validation of RP-HPLC method for the estimation of Sitagliptin phosphate in bulk and its tablet dosage form.” J. Adv. Pharm. Edu & Res., 2013, 3(4), 475-479.
- TANG Yao Li and Xiang WEN: “RP-HPLC determination of the content and the related substance of Sitagliptin phosphate,” Chinese J. Pharm. Anal., 2009, 29(3), 1370-1372.
- Abdl Naser Zaid, Yara Abu Zaaror and AimanKaddumi: “Stability of extemporaneously prepared sitagliptin phosphate solution,” PLOS ONE, 2022, 17(3), 1-12.
- Neha Sunil Dangi, S. R. Bavaskar and Dr. S. D. Barbate: “Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and tablet dosage form,” WJPR, 2016, 5(9), 773-781.
- Bhimireddy Venkata Rami Reddy, Nanduri Raman and Badam Sai Kumar: “Chiral separation of sitagliptin phosphate enantiomer by HPLC using amylose based chiral stationary phase,” J. Pharm. Res., 2013, 7, 546-550.
- R. Nageswara Rao, B. Sravan and K. Ramakrishna: “Precolumn o-pthalaldehyde-N-acetyl-L-cystenine derivatization followed by RP-HPLC sepration and fluorescence detection of sitagliptin enantiomers in rat plasma,” Chirality, 2013, 25(12), 883-889.
- Rasha M. Ahmed, Ghada M. Hadad and Ahemd E. El. Gendy: “Development of HPLC method for determination of Sitagliptin in human plasma using fluorescence detector by experimental design approach,” Analytical chemistry letters, 2018, 8(6), 813-828.
- Yao Tang, Xiang Li and Nie Wen: “Determination of sitagliptin phosphate in rat plasma by high performance liquid chromatographuy-tandem mass spectrometry,” National library of medicine, 2011, 2996), 475-480.
- Ravanello Aline, Schreiner Deigado Leila and Isa Pedroso Marcolino Ana: “A simple stability-indicating LC-UV method to assay sitagliptin phosphate in tablets,” Curr. Anal. Chem., 2012, 8(4), 569-573(5).
- Ramzia I.El-Bagary, Ehab F. Elkady and Bassam M. Ayoub: “Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product,” Talanta, 2011, 85(1), 673-680.
- Zhen Wang, Shujun Hu and Xiaoying Wu: “A highly sensitive LC-MS/MS method for the N-nitrosamine impurity in the sitagliptin phosphate monohydrate active pharmaceutical ingredient,” Anal. Methods, 2023, (3), 256-260.
- Amruta Dalal, Dr. Varsha Tegeli and Rajashri Waghmode: “Development and validation of a simple and rapid uv spectrophotometric method for linagliptin in bulk and marketed dosage form,” Der Pharma Chemica, 2022, 14(2), 23-26.
- Amar Gangadhar Zalte, Ravindranath BhanudasSaudagarand Pramod NanasahebKatkade: “Validated UV-spectroscopic estimation of linagliptin concentration in bulk and dosage form,” RES. J. PHARM. TECH., 2016, 9(5), 490-492.
- Sri K. Vijaya, Anusha A. and Sudhakar M.: “UV-spectrophotometry method for the estimation of linagliptin in bulk and pharmaceutical formulations, ASIAN J. RES. CHEM.,” 2016, 9(1), 47-50.
- Patil Chetan V. and Patil Paresh A.: “Development of validation of zero order, first-order, second-order, UV-Spectrophotometry methods using AUC technique for quantitative estimation of linagliptin in bulk material and tablets,” Asian J. Res. Chem., 2020, 13(3), 228-232.
- Sunitha Gurrala, Panikumar Durga Anumolu and Sahitya Menkana: “Spectrophotometric estimation of linagliptin using ion-pair complexation and oxidative coupling reactions- a green approach,” TJPS, 2020, 44(4), 245-250.
- J. N. Suresh kumar, B. Satya Prasad and M. Keerthana: “Quantitative analysis of linagliptin in its pharmaceutical dosage form by UV spectroscopy and RP-HPLC techniques, WJPR,” 11(11), 297-610.
- Heba A. Aref, Sherin F. Hammad and Mohamed Saleh Elgawish: “Novel spectrofluorimetric quantification of linagliptin in biological fluids expoiting its interaction with 4-chloro-7-nitrobenzofurazan,” The J. Bio. Chem. Lumine., 2020, 35(5), 626-635.
- Mahmoud A. Omar, Ahmed M. Haredy, Gamal A. Saleh, A. H. Nagger and Sayed M. Derayea: “Diarylpyrrolone based fluorophore for the selective spectrofluorometric method for determination of linagliptin antidiabetic drug in pharmaceutical tablets,” MICRO CHEM. J., 2019, 148, 555-560.
- Ramzia L. El-Bagary, Ehab F. Elkadyand Bassam M. Ayoub: “Liquid chromatographic determination of linagliptin in bulk, in plasma and in its pharmaceutical preparation,” IJBS, 2012, 8(3), 209-214.
- Lakshmi B. Reddy: “A novel RP-HPLC method for the quantification of linagliptin in formulations,” J. OF ATOMS AND MOLECULES, 2012, 2(2), 155-164.
- Kirtimaya Mishra, Balamurugan K. And Suresh R.: Linagliptin: “a review on bio-analytical and analytical methods,” IJPQA, 2018, 9(3), 225-230.
- Sara S. Mourad, Eman L.El-Kimary, Dalia A. Hamdyand Magda A. Barary: “Stability-indicating HPLC-DAD method for the determination of linagliptin in tablet dosage form: application to degradation kinetics,” J. CHROMATOGRAPH. SCI., 2016, 54(9), 1560-1566.
- Rajbangshi J. C., Alam M. M. and Hossain M. S. “:Development and validation of a RP-HPLC method for quantitative analysis of linagliptin in bulk and dosage forms,” Dhaka Uni. J. Pharmaceu. Sci., 2018, 17(2), 175-182.
- Abeer Hanafy and Hoda Mahgoub: “A validated HPLC method for the determination of linagliptin in rat plasma. Application to a pharmacokinetic study,” J. Chromatogr. Sci., 2016, 54(9), 1573-1577.
- Raquel Balestri Heleno Ferreira, Jonathaline Apollo Duarte and Flavio Dias Ferreira: “Biological safety studies and simultaneous determination of linagliptin and synthetic impurities by LC-PDA,” J. Anal. Methods Chem., 2019, 2019, 110-119.
- Venkata Naresh Kumar: “The determination of linagliptin using HPLC method,” The TamilnaduDr. M. G. R. Medical University Chennai-600 032, 2014, 80.
- S. Baokar, K. Mane and A. Bhujbal: “A current review on analytical tools for determination of new oral antidiabetic drugs, empagliflozin, linagliptin and biguanides in bulk materials,” pharmaceuticals and biological samples, IJPR, 2020, 32(34), 67-83.
- Sri K. Vijaya, Anusha M. and Reddy S. Ravinder: “A rapid RP-HPLC method development and validation for the analysis of linagliptinin bulk and pharmaceutical dosage form, Asian J. Pharmaceu.” Anal., 2015, 5(1), 16-20.
- Basar Al-Sabti And Jehad Harbali: “Trace analysis of potential genotoxic impurity N,N- dimethylaniline in linagliptin active pharmaceutical ingredient using HPLC, SSC,” 2020, 3(7), 306-312.
- BasarAl-sabti and Jehad harbali: “Quantitative determination of potential genotoxic impurity 3-aminopyridine in linagliptin active pharmaceutical ingredient using HILIC-UV, BMC,” 2020, 34(11).
- Bashar Al- Sabti and Jehad Harbali: “Development and validation of an analytical method for quantification of potential genotoxic impurity 4- dimethylaminopyridine in linagliptin active pharmaceutical ingredient using hydrophilic interaction liquid chromatography,” Sep. Sci. Plus, 2020, 3(9), 399-406.
- Nagaraj Kumar Nannapaneni, Sunil S Jalalpure and RajendraprasadMuppavarapu: “An ultra-high performance liquid chromatography- tandem mass spectrometry method for the quantification of linagliptin in human plasma, RSC Advances,” 2016, 6(71), 66756-66766.
- Xiao-Zhen Zheng, Xiao-di Han and Chang-Liang Wang: “Determination of linagliptin in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study,” Lat. Am. J. Pharm., 2016, 35(7), 1489-1494.
- K Venkata Rao, Raja Gorla and B. Sreenivasulu: “A simple and sensitive stability-indicating HPTLC assay method for the determination of linagliptin, Pharmacophore,” 2014, 5(5), 693-700.
- R. P. Bhole, S. B. Wankhede and Y. B. Zambare: “High performance thin layer chromatographic determination of linagliptin in pharmaceutical formulations and in biological samples,” Int. J. Pharmaceu. Chem. Anal., 2017, 4(1), 13-19.
- Deepika J., Bhavana S., Archana R. and Nidhi S.: “Analytical method development and validation of UV-visible spectrophotometric method for the estimation of saxagliptin in gastric medium,” Glob. J. Pharmaceu. Sci., 2020, 8(2), 0059-0065.
- Bhagyashri S. Shinde, M. S. kalshetti and Anjali P. Kokane: “UV-spectrophotometric method development and validation for estimation of saxagliptin in API and pharmaceutical dosage form,” Int. J. Curr. Pharmaceu. Res., 2020, 12(5), 63-66.
- Pathak and Bansal: “Analytical methods of saxagliptin a DPP-4 inhibitor: a review,” IJBPAS, 2021, 10(7), 2321-2324.
- K. Sravana Kumari and B. Sailaja: “Analytical method development and validation for estimation of dipeptidyl peptidase-4 inhibitors: a review,” Int. J. Curr. Res. Chem. Pharma. Sci., 2(4), 2015, 83-98.
- Marwa S. Muneeb: “Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations,” Bull. Fac. Pharm., Cairo Uni., 2013, 51, 139-150.
- Sabry Khalil, AfafBushara and Hanan Farag: “New analytical methods for the determination of two gliptin drugs in pharmaceutical formulation and urine samples,” Am. J. PharmTech. Res., 2020, 10(01), 31-43.
- Vaishali V. Karkhanis and Anandkumari D Captain: “Development and validation of a liquid chromatographic method for estimation of saxagliptin in tablet dosage form,” Asian J. Res. Chem., 2013, 6(6), 552-554.
- BoovizhikannanThangabalan, GetuKahsay, Adissu Alemayehu, HailekirosGebretsadik, TesfamichaelGebretsadikan and Ramalingam Kalaichelvi: “RPHPLC method for the estimation of saxagliptin in pure and its tablet dosage form,” IJSRED, 2020, 3(3), 1255-1263.
- Pathak Shilpi and Mishra Pradeep: “Determination of saxagliptin in bulk and pharmaceutical formulation using stability indicating RP-HPLC method with DAD detector,” Res. J. Chem. Environ., 2021, 25(4), 140-147.
- LaísEngroffScheeren, Ana Isa Pedroso Marcolino and Andréa Inês Horn Adams: “Stability indicating RP-LC-PDA method for the quantitative analysis of saxagliptin in pharmaceutical dosage form,” BJPS, 2015, 51(2), 461-466.
- GangaiAmaran, “Bio analytical method development and validation of saxagliptin in human plasma by RP-HPLC method,” KMCH Collage of Pharmacy Coimbatore, 2014, 71.
- Dr.Pradnyalokhande: “Development and validation of an HPLC method for the analysis of saxagliptin in bulk powder,” IJTSRD, 2020, 4(2), 37-41.
- Pathak S. and Bansal K.: “Analytical methods of saxagliptin a DPP-4 inhibitor: a review,” IJBPAS, 2021, 10(7), 2321-2334.
- Wael Abu Dayyih, Lina Tamimi, EyadMallah and Kenza Mansour: “Saxagliptin levels and its pharmacokinetic application in presence of sucralose in animal serum by HPLC method,” Int. J. Pharm. Pharm. Sci., 2015,7(9), 243-250.
- Hany A. batakoushy, Mahmoud A. Omar, Hytham M. Ahmed, Mohamed A. Abdel Hamid and Mohmoud M. Sebaiy: “Pharmacology and analytical chemistry profile of dapagliflozin, empagliflozin and saxaglptin,” J. Pharmaceu. Pharmacol. Res., 2022, 5(4), 44-53.
- Pawanjeet J. Chhabda, M. Balaji, Srinivasarao V., K. Ramakrishna and K. M. Ch. Apparao: “Development and validation of simple stability indicating RP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form,” Int. J. Res. Dev. Pharm. L. Sci., 2014, 3(3), 993-1003.
- P. Llayaraja, M. Manivannan and P. Parthiban: “A selective and sensitive method for the determination of sulfonate ester impurities in saxagliptin drug substance by HPLC, J. Pharmaceu.” Neg. Res., 2022, 13(5), 2028-2032.
- Dhara Vashi and Suresh Kumar: “Impurity identification and characterization of some anti-diabetic drugs using various analytical methods,” Asian J. Pharm. Res., 2019, 9(4), 243-248.
- N. Batta, N. R. Pilli, V. R. Derangula, H. B. Vurimindi, R. Damaramadugu and R. P. Yejella: “A rapid and sensitive LC-MS/MS assay for the determination of saxagliptin and its active metabolite 5-hydroxy saxagliptin in human plasma and its application to a pharmacokinetic study,” 2015, 65(3), 133-140.
- L. Sridhar, P. Goutami, D. Vijay Darshan, K. Ramakrishna, R. Nageswara Rao and S. Prabhakar: “LC-ESI-MS/MS studies on saxagliptin and its forced degradation products, Anal. Methods,” 2014, 6, 8212-8221.
- Jing-Wen Gao, Yue-Mei Yuan and Ya-Song Lu: “Development of rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study,” Biomed. Chromatogr., 2012, 26(12), 1482-1487.
- Gaikwad D. D., Patel S. G., Wamam S. A., Jadhav S. L., and Dhobale S. M.: “Method development and validation of saxagliptin hydrochloride by RP-HPLC method, Bull. Env. Pharmacol.” Life Sci., 2020, 9(9), 22-28.
- Md. Saifuil Islam, Md. Taleb Hossain, Sukalyan Kumar Kundu, Md. Abdul Halim and Md. Raffiquzzaman: “Development and validation of RP-HPLC method for determination of saxagliptin hydrochloride in bulk and tablet dosage form,” WJPPS, 2016, 5(5), 107-119.
- Dr.Safila Naveed, Hina Rehman and Fatima Qamar: “Method development and validation of vildagliptin using UV spectrophotometer,” LIPSR, 2014, 5(10), 714-717.
- Gayatri A. Gaikwad and Pranav P. Tambe: “Development and validation of UV spectroscopic method for estimation of vildagliptin in tablet dosage form,” EJBPS, 2022, 9(8), 427-432.
- Beena kumari, and Aparna Khansili: “Analytical method development and validation of UV-visible spectrophotometric method for the estimation of vildagliptin in gastric medium,” Drug Res(stuttg), 2020, 70(9), 417-423.
- Amanda T. Barden, Bruna L. Piccoli and Nadia M. Volpato: “Second-order derivative UV spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study,” Drug Anal. Res., 2018, 02, 46-53.
- Laoujain Anis Dayoub and FidaAmali: “Development of new visible spectrophotometric analytical method for determination of vildagliptin in bulk and pharmaceutical dosage forms,” Res. J. Pharm. Tech., 2020, 13(6), 2807-2810.
- Rao K. Hanumantha, Rao A. Lakshmana, and K. B. Chndraa: “Development and validation of HPLC method for the estimation of vildagliptin in pharmaceutical dosage form,” Int. J. Pharm. Chem. Bio. Sci., 2014, 4(2), 361-366.
- Charyulu, S.S. and Kumar, J. V. S.: “Development of a new related substance by HPLC method for vildagliptin for quantification of purity,” J. Pharm. Res. Int., 2022, 34(34A), 26-35.
- Padmanabh B. Deshpande, Saurabh R. Jadhav, Shraddha S. Jadhav, Sandeep Swami and Dipak Supe: “Chromatographic methods for determination of dipeptidyl peptidase-4(dpp-4) inhibitors,” IJPRIF,2021, 14(02), 199-212.
- Razia Sultana, Sitesh C. Bachar and Fatema Rahman: “Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC,” IJPLS, 2013, 4(4), 2530-2534.
- Vijay GovindraoNapateand Pratik AnantraoNapate: “Method development and validation for the vildagliptin by RP-HPLC method,” AJPAMC, 2020, 8(1), 24-31.
- A.M.Kashid, D. A. Ghorpade, P. P. Toranmaland S. C. Dhawale: “Development and validation of reversed phase HPLC method for the determination of vildagliptin using an experimental design,” J. Anal. Chem., 2015, 70, 510-515.
- Pragati Ranjan Satpathy, V. Mohan Goud, Bhoga Bhagya, JVC. Sharma and N. Shyamala: “Development and validation of a RP-HPLC method for the assay of vildagliptin,” Wrld. J. Pharm. Pharmaceu. Sci., 2014, 3(2), 2303-2310.
- Meetali M. Chaphekar and Purnima D. Hamrapurkar: “Development and validation of RP-HPLC assay method for vildagliptin using QBD approach and its forced degradation studies,” IJPSDR, 2016, 8(3), 157-165.
- ThangabalanBoovizhikannan and Vijayraj Kumar Palanirajan: “RP-HPLC determination of vildagliptin in pure and tablet formulation,” J. Pharm. Res., 2013, 7(1), 113-116.
- Jagdale Ramkrishna Rao Saheb, Dabhade M. and Kokate Shekhar Vikram P.: “RP-HPLC method development and validation of vildagliptin in bulk and dosage form,” WJPPS, 2017, 6(9), 1161-1176.
- Sharifa Sultana, Uttom Kumar, Md. Shahadat Hossain, Dilshad Noor Lira and Abu SharaShamsurRouf: “Qbd approach for the development and validation of RP-UHPLC method for quantitation of vildagliptin,” J. Pharmaceu. Sci., 2017, 16(1), 107-117.
- Shrinivas, C., Qureshi, H. K. And Veeresham C.: “Validated chiral ultra fast liquid chromatographic method for quantitative analysis of enantiomeric vildagliptin, American J.” Anal. Chem., 2021, 12(11), 429-439.
- Amanda Thomas Barden, Barbara Salamon, Elfrides Eva Sherman Schapoval and Martin Steppe: “Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product,” J.Chromatogram. Sci., 2012, 50(5), 426-432.
- Ayushman Tiwari, Vandana Arora Sethi, Arshad H. Khuroo and Lalit Kumar Tyagi: “Bioanalytical method development and validation of vildagliptin in rat plasma using LCMS/MS method,” J. Adv. Sci. Res., 2019, 10(3), 22-29.
- Sharif Arar, Enas Al-Qudah, Muhammad Alzweiriand Kamal Sweidan: “New forced degradation products of vildagliptin, identification structural elucidation using LC-MS, with proposed formation,” Journal Of Liquid Chromatographic And Related Technologies, 2020, 43(15-16), 633-644.
- De Andrade C., De Araujo Lock G., Pigatto M. C., Hass S. E. and De Araujo B. V.: “Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis,” Biomed. Chromatogr., 2014, 28(12), 1722-1727.
- Chaitali Dhale and Janhavi R. Rao: “Stability indicating HPLC-MS method for determination of degradation products in vildagliptin, J. Anal. Bioanal.” Tec., 2019, 10(2), 420.
- Bashar Al-Sabti And Jehad Harbali: “Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC-MS,” J. Anal. Sci., 2021, 44(13), 2587-2595.
- Santosh R. Butle and Padmanabh B. Deshpande: “Validated stability-indicating HPTLC method development for determination of vildagliptin as bulk drug and in tablet dosage form,” EJPMR, 2015, 2(6), 234-237.
- Amruta S. Khurd, Pankaj B. Miniyar, Sandip R. More, Kajal V. Doshi and Vandana Gawande: “Analytical method development and validation of vildagliptin by using quality by design approach,” EJBPS, 2020, 7(3), 223-229.
- Gayatri Dhobale, Priya Sahane, Suresh Jadhav and Dushyant Gaikwad: “A comprehensive review on analytical profile of anti-diabetic drug,” IJBPAS, 2021, 10(12), 331-352.
- A. V. V. N. K. Sunil Kumar, T. V. Reddy and C. B. Sekharan: “Utility of picric acid and 2,4 dinitrophenol as chromogenic reagents for visible spectrophotometric quantification of alogliptin,” Bull. Fac. Pharma., Cairo Uni., 2017, 55(1), 177-184.
- A. V. V. N. K. Sunil Kumar, T. V. Reddy and C. B. Sekharan: “Spectrophotometric determination of alogliptin in bulk and tablet dosage form using bromate-bromide mixture as bromination agent,” Karbala Int. J. Modern Sci., 2016, 3(1), 8-17.
- Mohamed M. Salim, Aya A. Marie, Amira H. Kamal, Sherin F. Hammad and Mahmoud M. Elkhoudary: “Using of eosin Y as a facile fluorescence probe in alogliptin estimation: application to tablet dosage forms and content uniformity testing, Spectrochimia Acta Part A: Molecular and Biomolecular Spectroscopy,” 2023, 285, 123-131.
- Sayed M. Dereyea, Ahmed A. Gahlan, Mahmoud A. Omar, Gamal A. Saleh and Ahmed M. Haredy: “Spectrofluorometric determination of alogliptin an antidiabetic drug in pure and tablet form using fluorescamine, a fluorogenic agent: application to content uniformity test, Luminescence,” 2020, 35(7), 1028-1035.
- Azza S. Tammam, Ahmed A. Gahlan, Mahmoud A. Taher and Ahmed M. Haredy: “Hantzsch condensation reaction as a spectrofluorometric method for determination of alogliptin, an antidiabetic drug, in pure form, tablet form, and human and rat plasma, Luminescence,” 2021, 37(4), 543-550.
- Yadav Priyanka J., Jadhav Sayali S. and Mohite S. K.: “Development and validation of RP-HPLC method for alogliptin benzoate in bulk drug and dosage form, IJPPR.Human,” 2014, 1(2), 1-9.
- SnigdhaDhamireddy, Dr. Sanjeev Kumar Subudhi, Veermalla Swetha, KallepelliShirisha, CheripelliSrinija and N. Sneha Sadashiv: “RP-HPLC method development and validation of alogliptin tablet dosage form,” 2019, 4(11), 43-50.
- Ingle Suyash, Tegeli Varsha, Birajdar Avinash and Nangare Gajanand: “Development and validation of rp-hplc method for the estimation of alogliptin in api and tablet formulation,” Res. J. Pharma. Tech., 2022, 15(4), 1791-1794.
- Ramzia I. El-Bagary, Ehab F. Elkady and Bassam M. Ayoub: “Liquid chromatographic determination of alogliptin in bulk and in its pharmaceutical preparation,” Int. J. Biomed. Sci., 2012, 8(3), 215-218.
- Charise DallazemBertol, Maria Tereza Friedrich, Graciela Carlos and Pedro Eduardo Froehlich: “Analytical stability-indicating methods for alogliptin in tablets by LC-CAD and LC-UV,” J. AOAT Int., 2017, 100(2), 400-405.
- Shivarudregowda GS, Jose Gnana Babu C. and Tamizh Mani T.: “Validated RP-HPLC method for the quantitation of alogliptin in bulk and tablet dosage form,” Am. J. PharmTech Res., 2018, 8(2), 140-148.
- A. Madhukar, Afreen Fathima, A. Usha, A. Satish Kumar Chary, A. Prashanth Kumar and K. Usha: “RP-HPLC method development and validation of alogliptin bulk and tablet dosage form,” IAJPS, 2018, 5(4), 2897-2904.
- Rakesh V. C., T. Srinivas Rao, Dr.Chandanman Sreedhar, Akkamma HG and Josef Yakin: “Development and validation of new RP-HPLC method for the determination of alogliptin benzoate on bulk form and dosage form,” JETIR, 2019, 6(4), 52-58.
- Bassam M. Ayoub: “Mini-review: analytical procedures for alogloptin determination in biological fluids and pharmaceutical formulations,” Der Pharma Chemica, 2016, 8(9), 18-22.
- Yatha Ravi and Bigala B. Rajkamal: “A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits,” J. Appl. Pharmaceu. Sci., 2019, 9(2), 29-37.
- Sabyaschi Biswal, Sumanta Mondal and Prasenjit Mondal: “Liquid chromatography-electro spray ionization-tandem mass spectroscopy method for the quantification of alogliptin in spiked human plasma,” Egypt. Pharmaceut. J., 2021, 20, 82-91.
- Hao CHEN, Xue XIA, Linjin LI, Wenbing JIANG, Yi WANG, Huixia XIA, Zhiyi WANG and Yilong WANG: “Pharmacokinetic and bioavailability study of alogliptin in rat plasma by UPLC-MS/MS,” Lat. Am. J. Pharm., 2016, 35(2), 233-241.
- Bashar Al-Sabti and Jehad Harbali: “HPLC-MS analysis of four genotoxic impurities in alogliptin pharmaceutical materials,” J. AOAC Int., 2022, 105(2), 362-369.
- Gayathri M. Nair and S. Malathi: “Alogliptin: a review of analytical methods,” EJBPS, 2021, 8(6), 267-271.
- Supriya P., Madhvi Latha N., Rohit H. KBV, Ramana GV, Harini U. and Pawar AKM: “Development and validation of UV spectrophotometric and reversed phase-high performance liquid chromatography - PDA methods for the estimation of alogliptin benzoate,” Asian J. Pharmaceu. Clinic. Res., 2016, 9(1), 282-287.
- P. J. Yadav, V. N. kadam and S. K. Mohite: “Development and validation of UV spectrophotometric method for alogliptin benzoate in bulk drug and tablet formulation,” J. Curr. Pharma Res., 2014, 4(4), 1286-1290.
- Heba A. Aref, Sherin F. Hammad, Khaled M. Darwish and Mohammed S. Elgawish: “Novel spectrofluorometric quantification of alogliptin benzoate in biofluids exploiting its interaction with 4-chloro-7-nitrobenzofuran, Luminescence,” 2019, 35(2), 284-291.
- Kun Zhang, Panqin Ma, Wenna Jing and Xiangrong Zhang: “A developed HPLC method for the determination of alogliptin benzoate and its potential impurities in bulk drug and tablets,” Asian J. Pharmaceu. Sci., 2015, 10, 152-158.
- Hani Naseef, Ramzi Moqadi and MoammlQurt: “Development and validation of an HPLC method for determination of antidiabetic drug alogliptin benzoate in bulk and tablets,” J. Ana. Methods Chem., 2018, 2018, 77-83.
- YuXia Zhou, WenTao Zhou, LiLi Sun, QiaoGen Zou, Ping Wei and PingKaiOuYang: “Characterization of process-related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed-phase high-performance liquid chromatography method,” J. Sep. Sci., 37(11), 1248-1255.
- Sherin F. Hammad, Inas A. Abdallah, Alaa Bedair and Fotouh R. Mansour: salting-out induced liquid-liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV, BMC Chem., 2021, 15(2), 256-265.
- G. Srinivasa Rao, K. Mallesh, G. Vijay Kumar, Ch. Surekha and B. Venugopala: “A validated chiral HPLC method for the enantiomeric purity of alogliptin benzoate, Der Pharma Chemica,” 2014, 6(3), 234-239.
- Surati Jasmina Shivlal, “Development and validation of stability indicating assay methods for estimation of anti diabetic drugs,” Gujarat Technological University Ahmedabad, 2020, 86,145,180.
- Shubhangi C. Daswadkar, Madhumita A. Roy, Sanjay G. Walode and C. B. Mahendra Kumar: optimization of RP-HPLC method for determination of alogliptin benzoate on bulk and dosage form, Int. J. Chem. Sci., 2016, 14(2), 649-660.
- Yuting Lu, Danyi Yang, Zhiyu Li, Taijun Hang and Min Song: Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques, J. Pharmaceu. Biomed. Ana., 2016, 128, 253-263.
- Komal Sharma and Amrita Parle: “Development and validation of HPTLC method for estimation of alogliptin benzoate in bulk drugs and tablet dosage forms,” Int. Bull. Drug Res., 2015, 5(8), 81-89.
- KunjanBharatkumarBodiwala, Shailesh Shah, Jeenal Thakor, Bhavin Marolia and Pintu Prajapati: “Degradation kinetics study of alogliptin benzoate in alkaline medium by validated stability-indicating HPTLC method,” J. AOAT Int., 2016, 99(6), 1505-1512.
- K. R. Patil, T. A. Deshmukh and V. R. Patil: “Stability indicating high performance thin layer chromatographic determination of alogliptin benzoate as bulk drug and in tablet dosage form,” Am. J. PharmTech Res., 2019, 9(3), 332-343.
- Vinyas M., Velivela Swapna, Yadav Gopi, Pati Nikunja B and Gupta VRM: “Analytical method development and validation of alogliptin by RP-HPLC method,” Res. J. Pharm. Tech., 2016, 9(7), 775-778.
- Maruthi R., Chandan R. S., Kumara Kinjal and Geetha R.: “Analytical method development and validation of teneligliptin by UV spectroscopy,” Res. J. Pharm. Tec., 2021, 14(1), 75-78.
- Kalyani V. Tighare and Amol V. Sawale: “Development and validation of stress degradation studies for quantification of teneligliptin by UV spectroscopic method,” WJPR, 2021, 10(7), 901-918.
- Sanket A. Kshirsagar, Sryesta B. Mane, Yogesh S. Hanchate, Aniket S. Katte and Kaushik V. Kulkarni: “UV spectrophotometric method development and validation for determination of teneligliptin hydrobromide in API and in pharmaceutical dosage form,” IJPRS, 2018, 7(1), 19-27.
- Pritam S. Jain, Prafulla M. Patil, Savita J. Sonawane and Sanjay J. Surana: “UV-AUC spectrophotometric method for quantitative estimation of teneligliptin,” ACTA Sci. Pharmaceu. Sci., 2019, 3(6), 43-47.
- Karthikeyan R., Ranjith Kumar B. and Muniyappan S.: “Validated colorimetric methods for the estimation of teneligliptin in tablets,” IDDT, 2017, 7(4), 38-40.
- Maruthi R., Kumara M. Kajal and Geetha R.: “Analytical method development and validation of teneligliptin by RP-UFLC,” Res. J. Pharm. Tec., 2020, 13(9), 4035-4040.
- Dr.PradnyaLokhande: “Analytical method development and validation of teneligliptin by using RP-HPLC with ICH guidelines,” IJTSRD, 2019, 3(3), 259-263.
- Biswas Bhanu, Kumar Manish, Sharma Jai Bharti and Saini Vipin: “Method development and validation for estimation of teneligliptin in tablet dosage form by RP-HPLC,” Res. J. Pharm. Tec., 2020, 13(4), 1774-1778.
- Bhoomi Dineshkumar Patel, Nidhi J. Dharsandiya and Ankit Chaudhary: “Development and validation of RP-HPLC method for estimation of teneligliptin and its impurity in tablet,” Int. j. pharm. Sci. res., 2021, 69(2), 127-133.
- S. Vidyadhara, Niteen Ashok Narkhede and Y. Sai. Silpa: “Method development, validation and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy,” J. Anal. Sci. tec.,2016, 7(27), 97-108.
- MukthinuthalapatiMathrusri Annapurna, Sara Almas, BaswaniRajasree and Angirekula Narendra: “Stability indicating ultrafast liquid chromatographic method for the estimation of teneligliptin,” Asian J. Pharmaceu., 2018, 12(2), S670-674.
- SrinivasuGunnam, ThirupathiChoppari, Narayana Chennuru Lakshmi and Sarah Imam Siddiqui: “Development and validation of teneligliptin stereoisomers by HPLC using cellulose based immobilized polysaccharide chiral stationary phase,” Curr. Pharmaceu. Anal., 2021, 17(10),1317-1322.
- Ganesh Prabhu K., “Analytical method development and validation for the estimation of teneligliptin in oral solid dosage form by reverse phase chromatographic technique using UHPLC,” The TamilnaduDr. M. G. R. Medical University, 2017, 88.
- Nallakumar P. and Siva Kumar R.: “Bioanalytical method development and validation of teneligliptin using RP-HPLC in rabbit plasma,” WJPR, 2017, 6(10), 589-602.
- Snigdha Rani Behera, Abhishek Mohapatra and Priyanka Rani Sahu: “Teneligliptin: a literature review on analytical and bio-analytical methods,” EJPMR, 2021, 8(11), 223-228.
- Pudi Rajesh and MukthinuthalapatiMathrusri Annapurna: “Validated isocratic liquid chromatographic method for the quantification of teneligliptin in the presence of internal standard,” Int. J. Grn. Pharm., 2018, 12(3), S670-S674.
- S. Shantikumar, N. Satheeshkumar and R. Srinivas: “Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor teneligliptin in rats using liquid chromatography-tandem mass spectrometry,” J. Chromatogr., 2015, 1002, 194-200.
- Sandesh R. Lodha, Karishma D. Patel, Sunny A. Patel and Shreya G. Patel: “Development and validation of HPTLC method for estimation of teneligliptin hydrobromide hydrate in tablet dosage form,” J. Pharm. Appl. Sci., 2016, 3(1), 26-33.
- Dimal A. Shah, Khushboo Agarwal, Falgun A. Mehta and Vandana B. Patel: “Stability indicating HPTLC method for the estimation of anti-diabetic drug teneligliptin,” Curr.Pharmaceu. Anal., 2018, 14(6), 547-554.
- Prafulla M. Patil, Pritam S. Jain, Sanjay J. Surana and Swati D. Yeole: “Development and validation of high-performance thin-layer chromatography method for estimation of teneligliptin in bulk and pharmaceutical formulation,” Arc. Nat. Med. Chem., 2017, 2017(2), 66-79.
- Murugan Maniavannan, PalaniappanIlayaraja and Paramasivam Parthiban: “Trace-level analysis of genotoxic sulfonate ester impurities in teneligliptin by GC-MS,” J. Appl. Pharm. Sci., 2022, 12(11), 052-060.
- Farkade Kalyani and Tawar Mukund: “Analytical method validation and quantitative analysis for active pharmaceutical ingredient and marketed formulation of teneligliptin hydrobromide by UV spectroscopy,” Asian J. Pharmaceu. Anal., 2021, 11(3), 195-198.
- Vishnu C. Shinde, Kiran B. Aher and Girija B. Bhavar: “Development and validation of UV spectrophotometric method and high performance thin layer chromatographic (HPTLC) method for estimation of teneligliptin hydrobromide in pharmaceutical preparation,” Scholars Res. Library, 2016, 8(8), 291-301.
- Bansode Ashwini S., Devhadrao Nitin V. and Shinde Ashwini C.: “Analytical method development and validation of teneligliptin hydrobromide in pure form by HPLC,” World J. Pharm. Sci.,2017, 5(10), 37-48.
- Nita Yadav and Anju Goyal: “Method development and validation of teneligliptin in pharmaceutical dosage form by UV spectrophotometric methods,” Int. J. Pharmaceu. Chem. Anal., 2017, 4(3), 54-58.
- Anvesha Vinit Ganorkar, Rekha S. Jibhkate and Krishna Radheshyam Gupta: “Development of stability indicating and robust RP-HPLC method for determination of teneligliptin,” AJACR, 2018, 1(4), 1-12.
- Girish D. Dahikar and Gayatri Bobade: “Development and validation of stability indicating RP-HPLC method for Teneligliptin hydrobromide hydrate,” AJPTR, 2020, 11(1), 45-56.
- Maruthi R., Chandan R.S. and Tengli Anand Kumar: “Characterization of impurities in teneligliptin hydrobromide hydrate by using LCMS/MS and NMR,” Res. J. Pharm. Tec., 2020, 13(8), 3569-3576.
- Sohan S. Chitlange, Diptee G. Rawat and Sejal P. Gandhi: “Estimation of anti diabetic teneligliptin in bulk and formulation by densitometric and spectrophotometric method,” Anal. Chem. Letters,2017, 7, 556-566.
- Wafaa A. Zaghary, Shereen Mowaka and Mostafa A. Hassan: “suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin,” Sci. Rep., 2017, 7(1), 112-123.
- K. durgaMalleshwar, B. Venugopala Rao and K. VenkateswaraRao: “A validated chiral HPLC method for the enantiomeric purity of trelagliptin,” Indo Am. J. Pharma. Res., 2019, 9(11), 582-587.
- Qi Wang, Xiuli Chen and CuiweiZhang: “dtermination of the enantiomeric purity of trelagliptin by pre-column derivatization and liquid chromatography on a chiral stationary phase,” Chromatographia, 2015, 78, 1395-1400.
- Xiao-Xia Hu, Tian Lan and Zhe Chen: “A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study,” J. Chromatogr. B, 2016, 1033-1034, 166-171.
- Li Zhou, Wang Xi and Hui Zhang: “The chiral bioconversion and pharmacokinetic analysis of trelagliptin in beagle dog plasma by LC-MS/MS,” J. Chroma. Sci., 2019, 58(1), 31-36.
- Zhiqiang Luo, Xinjing Chen and Guopeng Wang: “development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms,” European J. Pharma. Sci., 2018, 111, 458-464.
- Hui Zhang, Lili Sun and Liang Zou: “Identification, characterization and HPLC quantification of process-related impurities in trelagliptin succinate bulk drug: six identified as new compounds,” J. Pharma. Bio. Anal., 2016, 128, 18-27.
- Dr. Arjit Ancrao, Vikas Mundekar and Satish Jhon: “development and validation of related substances method by HPLC for analysis of trelagliptin succinate,” World J. Pharm. Pharma. Sci., 2016, 5(8), 1844-1858.
- Bassam M. Ayoub, Shereen Mowaka and Mona G. Arafa: “Factorial design optimization of micelle enhanced synchronous spectrofluorimetic assay of omarigliptin:Applied to content uniformity testing and in vitro drug release,” The J. Bio. Chem. Lumin., 2018, 33(4), 797-805.
- Juliana Emanuelli and Elfrides Eva SchermanSchapoval: “Stability- indicating HPLC method for estimation of omarigliptin in tablets – oxidative and photolytic kinetics and degredation products formed under oxidative conditions,” Microchemical Journal, 2020, 157, 105084.
- Mahmoud A Tantawy, Amal M Hassan and Maha A Hegazy: “Quality and stability profile assessment of the recent antidiabetic omarigliptin by using different chromatographic methods,” J. Chrom. Sci., 2021, 59(8), 762-769.
- Tesfaye Biftu, Ranabir Sinha-Roy and Ping Chen: “omarigliptin(MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes,” J. Med. Chem., 2014, 57(8), 3205-3212.
- Shereen Mowaka, NermeenAshoush and Mariam Tadros: “Enhanced extraction technique of omarigliptin from human plasma- applied to biological samples from healthy human volunteers,” Molecules, 2020, 25(18), 4232-4242.
- Meng-Fang li, Xiao-Xia Hu and Ai-Qun Ma: “Ultra-high pressure liquid chromatography- tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats,” Biomed. Chrom., 2017, 31(10), 991-1003.
- Amod S. Patil and Atul A. Shirkhedkar: “Development and validation of five simple UV-spectrophotometry methods for estimation of anagliptin in bulk and in-house tablets,” Pharm. Methods, 2016, 7(2), 127-131.
- Charu P. Pandya and Sadhana J. Rajput: “Stress degradation studies of anagliptin, development of validated stability indicating method, degradation kinetics study, identification and isolation of degradation products,” Chromatographia, 2018, 81, 1533-1550.
- K. Durga Malleswar, B. Venugopala Rao and S. Shylaja: “A validated chiral HPLC metod for the enantiomeric purity of anagliptin,” IAJPR, 2019, 9(7), 3096-3105.
- Amod Shivaji Patil and Atul Arun Shirkhedkar: “Application of quality by design in the development of HPTLC method for estimation of anagliptin in bulk and in-house tablets,” Eurasian J. Ana. Chem., 2017, 12(5), 443-458.
- Yogesh Purushottam Agrawal, Mona yogesh Agrawal and Siddhesh Bharat Jadhav: “Development and validation of novel UV spectrophotometric method for the determination of evogliptin in pharmaceutical dosage form,” Indian J. Pharmaceu. Edu. Res., 2020, 54(4), 1174-1179.
- Hetvi M. Ahir, Dulendra P. Damahe and Sachin B. Narkhede: “Development and validation of stability indicating RP-HPLC method for the estimation of evogliptin tartrate in pharmaceutical dosage form,” Int. J. Pharm. Sci. Rev. Res., 2022, 72(2), 1-6.
- Jagruti Dolas, Shailesh Jawarkar and Rani Jagdish Rode: “Novwlmwthod development, validation, and stability indicating assay method for evogliptin tartrate in pharmaceutical dosage form by RP-HPLC,” JETIR, 2022, 9(2), b327-b345.
- Arpit Patel, Rakesh Patel and Priyank Yadav: “Development and validation of RP-HPLC method for estimation of evogliptin in pharmaceutical dosage form,” Int. J. Pharmaceu. Res. App., 2021, 6(2), 775-781.
- Patel, K., Shah, U.A. & Patel, C.N. “Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design.” Futur J Pharm Sci., 2023,9, 1-12.
- Giri Prasad Goumutchu, Venkata NadhRatnakaram and SireeshaMallad: “Ninhydrin based visible spectrophotometric determination of gemigliptin,” Orient. J. Chem., 2019, 35(1), 363-369.
Diabetes refers to a metabolic disorder
identified by Hyperglycemia. Dipeptidyl peptidase-4
inhibitors (DPP-4 inhibitors) are also called as Gliptins
are a relatively new class of antidiabetic drugs to treat
type-2 diabetes. Analytical method development and
validation play an indispensable role in analysis and
manufacture of pharmaceuticals. The intent of this
article is to study the reported analytical methods in the
literature for assessment of Dipeptidyl peptidase- 4
inhibitors. This review covers divergent analytical
methods for the estimation of these drugs. Many
spectroscopic and chromatographic techniques are
available for the determination and evaluation of these
drugs in bulk and pharmaceutical preparation. Newly
evolved and advanced chromatographic techniques are
also available for the estimation of these drugs in
biological fluids such as Liquid Chromatography-
Tandem Mass Spectroscopy (LC- MS/MS), Gas
Chromatography- Mass Spectroscopy (GC- MS), High
Performance Liquid Chromatography- Mass
Spectroscopy (HPLC-MS) and Ultra- Fast Liquid
Chromatography (UFLC). The development and
validation of analytical methods is imperative for drug
development studies and even for the development of
drug formulation including stability and degradation
studies and also for the determination of
pharmacokinetic data of these drugs. This review work
summaries the current position of analytical methods for
estimation of these antidiabetic drugs in bulk, dosage
form and biological fluids.